-
Subject Areas on Research
-
2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel.
-
2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.
-
2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours.
-
46,XY/46,XY,21q- mosaicism in an infant with neutropenia and properdin deficiency.
-
A Comparison of Proposed Biosimilar LA-EP2006 and Reference Pegfilgrastim for the Prevention of Neutropenia in Patients With Early-Stage Breast Cancer Receiving Myelosuppressive Adjuvant or Neoadjuvant Chemotherapy: Pegfilgrastim Randomized Oncology (Supportive Care) Trial to Evaluate Comparative Treatment (PROTECT-2), a Phase III, Randomized, Double-Blind Trial.
-
A comparative study of the generation of dendritic cells from mobilized peripheral blood progenitor cells of patients undergoing high-dose chemotherapy.
-
A cost analysis of hematopoietic colony-stimulating factors.
-
A multi-institutional evaluation of factors predictive of toxicity and efficacy of bevacizumab for recurrent ovarian cancer.
-
A multicenter, phase II study of maintenance azacitidine in older patients with acute myeloid leukemia in complete remission after induction chemotherapy.
-
A novel approach to maintain planned dose chemotherapy on time: a decision-making tool to improve patient care.
-
A phase I study of the safety and pharmacokinetics of edotecarin (J-107088), a novel topoisomerase I inhibitor, in patients with advanced solid tumors.
-
A phase I trial of ifosfamide, mesna, and cisplatin in advanced non-small cell lung cancer. A cancer and leukemia group B study.
-
A phase I trial of recombinant human interleukin-1 beta alone and in combination with myelosuppressive doses of 5-fluorouracil in patients with gastrointestinal cancer.
-
A phase II trial of carboplatin/vinorelbine with pegfilgrastim support for the treatment of patients with advanced non-small cell lung cancer.
-
A pilot study comparing the neutropenic diet to a non-neutropenic diet in the allogeneic hematopoietic stem cell transplantation population.
-
A predictive model for neutropenia associated with cancer chemotherapy.
-
A radiologic syndrome after high dose chemotherapy and autologous bone marrow transplantation, with clinical and pathologic features of systemic candidiasis.
-
A randomized comparative trial of stavudine (d4T) versus zidovudine (ZDV, AZT) in children with human immunodeficiency virus infection. AIDS Clinical Trials Group 240 Team.
-
A randomized controlled phase III trial of recombinant human granulocyte colony-stimulating factor (filgrastim) for treatment of severe chronic neutropenia.
-
A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111.
-
A single institutional review of pediatric Bacillus spp. bloodstream infections demonstrates increased incidence among children with cancer.
-
A study of filgrastim (rG-CSF) priming of etoposide/cisplatin in advanced non-small cell lung cancer.
-
ALPS-Like Phenotype Caused by ADA2 Deficiency Rescued by Allogeneic Hematopoietic Stem Cell Transplantation.
-
Adjuvant sequential chemotherapy with doxorubicin plus cyclophosphamide, methotrexate, and fluorouracil (ACMF) with concurrent radiotherapy in resectable advanced breast cancer.
-
Aerosolized antifungal prophylaxis: the winds of change?
-
Agents under investigation for the treatment and prevention of neutropenia.
-
Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndrome.
-
An initial genetic analysis of gemcitabine-induced high-grade neutropenia in pancreatic cancer patients in CALGB 80303 (Alliance).
-
Analysis of Factors Associated With In-hospital Mortality in Lung Cancer Chemotherapy Patients With Neutropenia.
-
Anti-epidermal growth factor receptor therapy for glioblastoma in adults.
-
Antibodies to granulocyte precursors in selective myeloid hypoplasia and other suspected autoimmune neutropenias: use of HL-60 cells as targets.
-
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.
-
Are we finally ready for outpatient management of febrile neutropenia?
-
Association between bone marrow dosimetric parameters and acute hematologic toxicity in anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy.
-
Balancing the benefits and costs of colony-stimulating factors: a current perspective.
-
Biosimilars: are they ready for primetime in the United States?
-
Can Ceftazidime-Avibactam and Aztreonam Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae?
-
Candidemia in women with breast carcinoma treated with high-dose chemotherapy and autologous bone marrow transplantation.
-
Central line-associated bloodstream infections in adult hematology patients with febrile neutropenia: an evaluation of surveillance definitions using differential time to blood culture positivity.
-
Change in serum procalcitonin (deltaPCT) predicts the clinical outcome of children admitted with febrile neutropenia.
-
Chemotherapy dose intensity and quality cancer care.
-
Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management.
-
Chronic neutropenia: diagnostic approach and prognosis.
-
Clinical uses of pegylated pharmaceuticals in oncology.
-
Clostridium septicum abscess in hepatic metastases: successful medical management.
-
Colonization With Levofloxacin-resistant Extended-spectrum β-Lactamase-producing Enterobacteriaceae and Risk of Bacteremia in Hematopoietic Stem Cell Transplant Recipients.
-
Colony stimulating factors for chemotherapy induced febrile neutropenia.
-
Colony-stimulating factor use in the context of refined risk and benefit assessments.
-
Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials.
-
Colony-stimulating factors: clinical applications.
-
Comparison of EP2006, a filgrastim biosimilar, to the reference: a phase III, randomized, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy.
-
Comparison of caspofungin and amphotericin B for invasive candidiasis.
-
Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: a meta-analysis of randomized controlled trials.
-
Cost effectiveness of myeloid growth factors in cancer chemotherapy.
-
Cost-effectiveness of pegfilgrastim versus 6-day filgrastim primary prophylaxis in patients with non-Hodgkin's lymphoma receiving CHOP-21 in United States.
-
Cost-effectiveness of pegfilgrastim versus filgrastim primary prophylaxis in women with early-stage breast cancer receiving chemotherapy in the United States.
-
Cost-effectiveness of posaconazole versus fluconazole or itraconazole in the prevention of invasive fungal infections among neutropenic patients in the United States.
-
Cost-effectiveness of primary versus secondary prophylaxis with pegfilgrastim in women with early-stage breast cancer receiving chemotherapy.
-
Costs associated with febrile neutropenia in the US.
-
Cyclophosphamide in combination with sargramostim for treatment of recurrent medulloblastoma.
-
Cyclophosphamide-asparaginase- vincristine-prednisone induction therapy in childhood acute lymphocytic and nonlymphocytic leukemia.
-
Decision analysis of hematopoietic growth factor use in patients receiving cancer chemotherapy.
-
Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial.
-
Disruption of a nonribosomal peptide synthetase in Aspergillus fumigatus eliminates gliotoxin production.
-
Dose escalation trial of cyclophosphamide with Sargramostim in the treatment of central nervous system (CNS) neoplasms.
-
Dose intensity and hematologic toxicity in older breast cancer patients receiving systemic chemotherapy.
-
Dose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapy.
-
Dose-escalated cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE) chemotherapy for patients with diffuse lymphoma: Cancer and Leukemia Group B studies 8852 and 8854.
-
Duffy (Fy), DARC, and neutropenia among women from the United States, Europe and the Caribbean.
-
Dyshematopoiesis in combined immune deficiency with congenital neutropenia.
-
EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours.
-
Economic analysis of prophylactic pegfilgrastim in adult cancer patients receiving chemotherapy.
-
Economic impact of granulopoiesis stimulating agents on the management of febrile neutropenia.
-
Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial.
-
Effect of outpatient treatment of febrile neutropenia on the risk threshold for the use of CSF in patients with cancer treated with chemotherapy.
-
Effect of primary prophylactic G-CSF use on systemic therapy administration for elderly breast cancer patients.
-
Effect of primary prophylactic granulocyte-colony stimulating factor use on incidence of neutropenia hospitalizations for elderly early-stage breast cancer patients receiving chemotherapy.
-
Effectiveness of Granulocyte Colony-Stimulating Factor in Hospitalized Infants with Neutropenia.
-
Effects of IL-1 on hematopoietic progenitors after myelosuppressive chemoradiotherapy.
-
Effects of indirect and additional direct costs on the risk threshold for prophylaxis with colony-stimulating factors in patients at risk for severe neutropenia from cancer chemotherapy.
-
Efficacy and toxicity of doxorubicin/cyclophosphamide maintenance therapy in dogs with multicentric lymphosarcoma.
-
Efficacy of intravenous gamma globulin in autoimmune-mediated pediatric blood dyscrasias.
-
Enterococcus species and the central line-associated bloodstream infection surveillance definition: evaluating the importance of blood culture contamination.
-
Evaluating a critically ill patient with metabolic acidosis: the ifosfamide paradigm.
-
Evaluation of clinical outcomes of prophylactic versus preemptive cytomegalovirus strategy in liver transplant recipients.
-
Evidence-based use of colony-stimulating factors in elderly cancer patients.
-
Fatal, disseminated Acremonium strictum infection in a neutropenic host.
-
Febrile neutropenia and related complications in breast cancer patients receiving pegfilgrastim primary prophylaxis versus current practice neutropaenia management: results from an integrated analysis.
-
Filgrastim in patients with neutropenia: potential effects on quality of life.
-
Fixed-dose pegfilgrastim is safe and allows neutrophil recovery in patients with non-Hodgkin's lymphoma.
-
G-CSF as prophylaxis of febrile neutropenia in SCLC.
-
Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804.
-
Genome-wide association study of interferon-related cytopenia in chronic hepatitis C patients.
-
Granulocyte colony-stimulating factors: finding the right indication.
-
Granulocyte-colony stimulating factor use and medical costs after initial adjuvant chemotherapy in older patients with early-stage breast cancer.
-
Guideline for the management of fever and neutropenia in children with cancer and/or undergoing hematopoietic stem-cell transplantation.
-
Guidelines of the National Comprehensive Cancer Network on the use of myeloid growth factors with cancer chemotherapy: a review of the evidence.
-
Hematologic toxicity of high-dose iodine-131-metaiodobenzylguanidine therapy for advanced neuroblastoma.
-
Hematopoietic growth factors in the reduction of chemotherapeutic toxicity.
-
Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications.
-
Hematopoietic growth factors: ESMO recommendations for the applications.
-
Hemopoietic reserve in the older cancer patient: clinical and economic considerations.
-
Hepatic candidiasis: persistent pyrexia in a patient with acute myeloid leukaemia after recovery from consolidation therapy-induced neutropenia.
-
High-dose doxorubicin, dexrazoxane, and GM-CSF in malignant mesothelioma: a phase II study-Cancer and Leukemia Group B 9631.
-
High-dose, single-agent irinotecan as first-line therapy in the treatment of metastatic colorectal cancer.
-
Hodgkin lymphoma treatment with ABVD in the US and the EU: neutropenia occurrence and impaired chemotherapy delivery.
-
Hyper IgM Syndrome: a Report from the USIDNET Registry.
-
Ibrutinib-associated invasive fungal diseases in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: An observational study.
-
Impact of chemotherapy dose intensity on cancer patient outcomes.
-
Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review.
-
Impact of sarcopenia on treatment tolerance in United States veterans with diffuse large B-cell lymphoma treated with CHOP-based chemotherapy.
-
Implementing an evidence-based risk assessment tool to predict chemotherapy-induced neutropenia in women with breast cancer.
-
Improving the management of chemotherapy-induced neutropenia.
-
Infectious and bleeding complications in patients with glycogenosis Ib.
-
Inflammation triggers emergency granulopoiesis through a density-dependent feedback mechanism.
-
Influence of filgrastim (granulocyte colony-stimulating factor) on human immunodeficiency virus type 1 RNA in patients with cytomegalovirus retinitis.
-
Institutional experience with voriconazole compared with liposomal amphotericin B as empiric therapy for febrile neutropenia.
-
Interactive discussion on chemotherapy-related adverse events.
-
Interferon-alpha with zidovudine: safety, tolerance, and clinical and virologic effects in patients with Kaposi sarcoma associated with the acquired immunodeficiency syndrome (AIDS)
-
Introduction. Neutropenia risk models in oncology.
-
Introduction: pegfilgrastim, a new era in the management of chemotherapy-induced neutropenia.
-
Length of stay and mortality associated with febrile neutropenia among children with cancer.
-
Leukopenia, neutropenia, and reduced hemoglobin levels in healthy American blacks.
-
Lipid formulations of amphotericin B for empirical treatment of fever and neutropenia.
-
Lithium therapy in childhood neutropenia.
-
Liver transplantation for glycogen storage disease types I, III, and IV.
-
Long-term outcomes of myeloid growth factor treatment.
-
Long-term survival follow-up of atezolizumab in combination with platinum-based doublet chemotherapy in patients with advanced non-small-cell lung cancer.
-
Longitudinal Toxicity over Time (ToxT) analysis to evaluate tolerability: a case study of lenalidomide in the CALGB 50401 (Alliance) trial.
-
Lymphadenopathy as the primary manifestation of malignant transformation in two patients with severe congenital neutropenia.
-
Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study-CALGB 30607 (Alliance).
-
Management of chemotherapy in a pregnancy complicated by a large neuroblastoma.
-
Management of invasive mycoses in hematology patients: current approaches.
-
Mortality in patients after a recent myocardial infarction: a randomized, placebo-controlled trial of azimilide using heart rate variability for risk stratification.
-
Mortality rates in comparative trials of formulations of amphotericin B.
-
Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients.
-
Mutations in the chemokine receptor gene CXCR4 are associated with WHIM syndrome, a combined immunodeficiency disease.
-
Myeloid growth factors clinical practice guidelines in oncology.
-
Myeloid growth factors.
-
Myeloid growth factors.
-
Myeloid growth factors.
-
Myeloid growth factors. Clinical practice guidelines in oncology.
-
Myeloid-Specific Deletion of Mcl-1 Yields Severely Neutropenic Mice That Survive and Breed in Homozygous Form.
-
Myelotoxicity and dose intensity of chemotherapy: reporting practices from randomized clinical trials.
-
Myelotoxicity from chemotherapy.
-
Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801.
-
Neuroleptic-induced neutropenia in the elderly.
-
Neutropenia Precautions for Children Receiving Chemotherapy or Stem Cell Transplantation for Cancer.
-
Neutropenia as a potential pharmacodynamic marker for docetaxel-based chemotherapy in men with metastatic castration-resistant prostate cancer.
-
Neutropenia in glycogen storage disease Ib: outcomes for patients treated with granulocyte colony-stimulating factor.
-
Neutropenia, fever, and infection in children with acute lymphocytic leukemia.
-
Neutrophil growth factors.
-
Once-per-cycle pegfilgrastim (Neulasta) for the management of chemotherapy-induced neutropenia.
-
Opportunistic fungal pneumonia.
-
Outpatient consolidation treatment with clofarabine in a phase 2 study of older adult patients with previously untreated acute myelogenous leukemia.
-
Paclitaxel for the treatment of progressive or recurrent childhood brain tumors: a pediatric oncology phase II study.
-
Patients aged > or = 70 are at high risk for neutropenic infection and should receive hemopoietic growth factors when treated with moderately toxic chemotherapy.
-
Patterns of chemotherapy-associated toxicity and supportive care in US oncology practice: a nationwide prospective cohort study.
-
Pegfilgrastim administered once per cycle reduces incidence of chemotherapy-induced neutropenia.
-
Pegfilgrastim primary prophylaxis vs. current practice neutropenia management in elderly breast cancer patients receiving chemotherapy.
-
Pegfilgrastim: a granulocyte colony-stimulating factor with sustained duration of action.
-
Pegfilgrastim: the promise of pegylation fulfilled.
-
Personalized medicine and cancer supportive care: appropriate use of colony-stimulating factor support of chemotherapy.
-
Pharmacoeconomics of the myeloid growth factors: a critical and systematic review.
-
Phase 1 dose escalation trial of the safety and pharmacokinetics of cabozantinib concurrent with temozolomide and radiotherapy or temozolomide after radiotherapy in newly diagnosed patients with high-grade gliomas.
-
Phase 1b study of new posaconazole tablet for prevention of invasive fungal infections in high-risk patients with neutropenia.
-
Phase I clinical and plasma and cellular pharmacological study of topotecan without and with granulocyte colony-stimulating factor.
-
Phase I evaluation of mitoxantrone alone and combined with whole body hyperthermia in dogs with lymphoma.
-
Phase I evaluation of prolonged-infusion gemcitabine with irinotecan for relapsed or refractory leukemia or lymphoma.
-
Phase I trial of combined irinotecan and oxaliplatin given every three weeks to patients with metastatic colorectal cancer.
-
Phase I/II study of preoperative oxaliplatin, fluorouracil, and external-beam radiation therapy in patients with locally advanced rectal cancer: Cancer and Leukemia Group B 89901.
-
Phase II evaluation of aclarubicin in advanced breast cancer: a Southeastern Cancer Study Group trial.
-
Phase II randomized study of dose-dense docetaxel and cisplatin every 2 weeks with pegfilgrastim and darbepoetin alfa with and without the chemoprotector BNP7787 in patients with advanced non-small cell lung cancer (CALGB 30303).
-
Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma.
-
Phase II study of induction cisplatin and irinotecan followed by concurrent carboplatin, etoposide, and thoracic radiotherapy for limited-stage small-cell lung cancer, CALGB 30206.
-
Phase II trial of 5-fluorouracil plus eniluracil in patients with advanced pancreatic cancer: a Southwest Oncology Group study.
-
Phase II trial of weekly paclitaxel and gemcitabine for previously untreated, stage IIIB-IV nonsmall cell lung cancer.
-
Phase II trials of dolastatin-10 in advanced pancreaticobiliary cancers.
-
Pooled analysis of two randomized, double-blind trials comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancer.
-
Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.
-
Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy.
-
Predicting the risk of bacteremia in childen with fever and neutropenia.
-
Predictors of chemotherapy-induced neutropenia and its complications: results from a prospective nationwide registry.
-
Predictors of reduced dose intensity in patients with early-stage breast cancer receiving adjuvant chemotherapy.
-
Predictors of severe and febrile neutropenia during primary chemotherapy for ovarian cancer.
-
Prevalence and Etiology of Community-acquired Pneumonia in Immunocompromised Patients.
-
Prevention and early treatment of invasive fungal infection in patients with cancer and neutropenia and in stem cell transplant recipients in the era of newer broad-spectrum antifungal agents and diagnostic adjuncts.
-
Prevention and treatment of chemotherapy-induced neutropenia.
-
Prophylactic colony-stimulating factors in children receiving myelosuppressive chemotherapy: a meta-analysis of randomized controlled trials.
-
Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: a meta-analysis.
-
Prophylactic intravenous amphotericin B in neutropenic autologous bone marrow transplant recipients.
-
Prophylaxis of chemotherapy-induced febrile neutropenia with granulocyte colony-stimulating factors: where are we now?
-
Proposed biosimilar pegfilgrastim (LA-EP2006) compared with reference pegfilgrastim in Asian patients with breast cancer: an exploratory comparison from two Phase III trials.
-
Quality management of potential chemotherapy-induced neutropenic complications: evaluation of practice in an academic medical center.
-
Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy.
-
Randomized, double-blind study comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancer.
-
Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma.
-
Recombinant human granulocyte colony-stimulating factor therapy for patients with neutropenia and/or neutrophil dysfunction secondary to glycogen storage disease type 1b.
-
Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer.
-
Reduction of exit-site infections of tunnelled intravascular catheters among neutropenic patients by sustained-release chlorhexidine dressings: results from a prospective randomized controlled trial.
-
Reduction of oral mucositis by filgrastim (r-metHuG-CSF) in patients receiving chemotherapy.
-
Renal function in high dose chemotherapy and autologous hematopoietic cell support treatment for breast cancer.
-
Reporting of myelotoxicity associated with emerging regimens for the treatment of selected solid tumors.
-
Reversal of radiation-induced neutropenia by granulocyte colony-stimulating factor.
-
Reversion mutations in patients with leukocyte adhesion deficiency type-1 (LAD-1).
-
Risk Factors for Invasive Fungal Disease in Pediatric Cancer and Hematopoietic Stem Cell Transplantation: A Systematic Review.
-
Risk and healthcare costs of chemotherapy-induced neutropenic complications in women with metastatic breast cancer.
-
Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma.
-
Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice.
-
Risk assessment and guidelines for first-cycle colony-stimulating factor use in the management of chemotherapy-induced neutropenia.
-
Risk assessment in oncology clinical practice. From risk factors to risk models.
-
Risk models for predicting chemotherapy-induced neutropenia.
-
Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin's lymphoma receiving CHOP chemotherapy.
-
Risk of mortality in patients with cancer who experience febrile neutropenia.
-
Risks and consequences of chemotherapy-induced neutropenia.
-
Safety Profile of Biosimilar Filgrastim (Zarzio/Zarxio): A Combined Analysis of Phase III Studies.
-
Safety and efficacy of alternating treatment with EP2006, a filgrastim biosimilar, and reference filgrastim: a phase III, randomised, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy.
-
Safety and efficacy of pegfilgrastim in patients receiving myelosuppressive chemotherapy.
-
Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections.
-
Safety of bevacizumab in patients with metastatic breast cancer.
-
Selective antimicrobial modulation of human microbial flora.
-
Sequential high-dose ifosfamide, carboplatin and etoposide with rituximab for relapsed Hodgkin and large B-cell non-Hodgkin lymphoma: increased toxicity without improvement in progression-free survival.
-
Sequential prophylactic oral and empiric once-daily parenteral antibiotics for neutropenia and fever after high-dose chemotherapy and autologous bone marrow support.
-
Shifting guidelines for myeloid growth factors: applications in cancer chemotherapy.
-
Short-term costs associated with primary prophylactic G-CSF use during chemotherapy.
-
Significance of Clostridium tertium bacteremia in neutropenic and nonneutropenic patients: review of 32 cases.
-
Staphylococcus aureus bacteremia in patients with neutropenia.
-
Summary and comparison of myeloid growth factor guidelines in patients receiving cancer chemotherapy.
-
Summary and comparison of myeloid growth factor guidelines in patients receiving cancer chemotherapy.
-
T cell large granular lymphocyte leukemia associated with rheumatoid arthritis and neutropenia.
-
Thalidomide as salvage therapy for chronic graft-versus-host disease.
-
The colony-stimulating factors: use to prevent and treat neutropenia and its complications.
-
The economics of febrile neutropenia: implications for the use of colony-stimulating factors.
-
The economics of the colony-stimulating factors in the prevention and treatment of febrile neutropenia.
-
The efficacy of azimilide in the treatment of atrial fibrillation in the presence of left ventricular systolic dysfunction: results from the Azimilide Postinfarct Survival Evaluation (ALIVE) trial.
-
The impact of Filgrastim schedule variation on hematopoietic recovery post-chemotherapy.
-
The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials.
-
The impact of the host on fungal infections.
-
The impact of therapy with filgrastim (recombinant granulocyte colony-stimulating factor) on the health care costs associated with cancer chemotherapy.
-
The relationship of polymorphisms in ABCC2 and SLCO1B3 with docetaxel pharmacokinetics and neutropenia: CALGB 60805 (Alliance).
-
The role of hematopoietic growth factors in support of ifosfamide/carboplatin/etoposide chemotherapy.
-
The use of G-CSF during craniospinal irradiation.
-
The use of an intrathecal pump to manage intractable cancer pain in a pediatric patient: a case report.
-
Therapeutic use of granulocyte colony-stimulating factors for established febrile neutropenia: effect on costs from a hospital perspective.
-
Thromboembolism in hospitalized neutropenic cancer patients.
-
Ticlopidine-associated pancytopenia: implications of an acetylsalicylic acid alternative.
-
Trimethoprim-sulfamethoxazole therapy. Everything's not turning up roses.
-
Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study.
-
Unreported Missense Mutation in the Dimerization Domain of ADA2 Leads to ADA2 Deficiency Associated with Severe Oral Ulcers and Neutropenia in a Female Somalian Patient-Addendum to the Genotype-Phenotype Puzzle.
-
Update on neutropenia and myeloid growth factors.
-
Use of ED and hospital services for patients with acute leukemia after induction therapy: one year follow-up.
-
Use of re-randomized data in meta-analysis.
-
Utility of obtaining blood cultures in febrile neutropenic patients undergoing bone marrow transplantation.
-
Vinorelbine (Navelbine)/carboplatin combination therapy: dose intensification with granulocyte colony-stimulating factor.
-
Visual improvement despite radiologically stable disease after treatment with carboplatin in children with progressive low-grade optic/thalamic gliomas.
-
Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever.
-
Withholding antibiotics from patients with febrile neutropenia.
-
Zidovudine-induced neutropenia: are we too cautious?
-
[Malignant melanoma: hepatic intra-arterial chemotherapy].
-
Keywords of People